Conclusions
PSA failure
SECONDARY
In this secondary analysis of a randomized clinical trial of nonmetastatic unfavorable-risk PC, we found that being younger than 70 years, having a PSA of 10 ng/mL or more, and having a Gleason score of 8 to 10 could be used to estimate the shorter time to PSA failure following initial treatment with ADT and RT with or without docetaxel. These results support identifying males at very high risk for early PSA failure who may benefit from treatment escalation and could be studied in the setting of a prospective randomized clinical trial.